
“Targeting DNA repair in cancer: current state and novel approaches” 4bases’ paper of the month
We always hear about the highly celebrated Precision Medicine, but what is this in reality? An answer might be “the possibility to adopt a very
We always hear about the highly celebrated Precision Medicine, but what is this in reality? An answer might be “the possibility to adopt a very
4bases proudly announces a new important step in its development plan. Thanks to an exclusive commercial partnership with the ILC Group, 4bases’ products and services
Manno, March 31, 2020 4bases SA, a swiss-based company specialized in the development, production and commercialization of reagent kits for NGS (New Generation Sequencing) is
Custom panel – developed on-demand for your specific RUO or CE-IVD specific applications.
To make your choice easier and faster 4bases’ company and product information are gathered in the new brochure
Manno, December 3st, 2019. 4bases SA, a Swiss-based company specialized in the development, production, and commercialization of reagent kits and gene assays for clinical NGS,
Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved
After the renewal of our ISO13485:2016 certification in May, the entry of new products in our pipeline and the opening of new markets, the Swiss
Powered by Lifency SA © 2025